NASDAQ:SCPH - Scpharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $3.57 +0.16 (+4.69 %) (As of 05/26/2019 03:46 PM ET)Previous Close$3.57Today's Range$3.3910 - $3.7052-Week Range$2.44 - $14.36Volume116,172 shsAverage Volume51,692 shsMarket Capitalization$66.33 millionP/E RatioN/ADividend YieldN/ABeta1.31 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix that consists of proprietary subcutaneous formulation of furosemide, which is delivered through the SmartDose drug delivery system for treatment of congestion in decompensated heart failure patients outside of the acute care setting. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. to incorporate SmartDose drug delivery system with Furoscix. The company was founded in 2013 and is headquartered in Burlington, Massachusetts. Receive SCPH News and Ratings via Email Sign-up to receive the latest news and ratings for SCPH and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SCPH Previous Symbol CUSIPN/A CIK1604950 Webhttp://www.scpharma.com/ Phone617-517-0730Debt Debt-to-Equity Ratio0.10 Current Ratio8.50 Quick Ratio8.50Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.79 per share Price / Book0.94Profitability EPS (Most Recent Fiscal Year)($1.59) Net Income$-29,440,000.00 Net MarginsN/A Return on Equity-36.66% Return on Assets-30.57%Miscellaneous Employees21 Outstanding Shares18,580,000Market Cap$66.33 million Next Earnings Date8/13/2019 (Estimated) OptionableNot Optionable Scpharmaceuticals (NASDAQ:SCPH) Frequently Asked Questions What is Scpharmaceuticals' stock symbol? Scpharmaceuticals trades on the NASDAQ under the ticker symbol "SCPH." How were Scpharmaceuticals' earnings last quarter? Scpharmaceuticals Inc (NASDAQ:SCPH) released its quarterly earnings results on Wednesday, May, 8th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.52) by $0.05. View Scpharmaceuticals' Earnings History. When is Scpharmaceuticals' next earnings date? Scpharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, August 13th 2019. View Earnings Estimates for Scpharmaceuticals. What price target have analysts set for SCPH? 4 equities research analysts have issued twelve-month price objectives for Scpharmaceuticals' shares. Their forecasts range from $5.00 to $14.00. On average, they anticipate Scpharmaceuticals' stock price to reach $10.3333 in the next twelve months. This suggests a possible upside of 189.4% from the stock's current price. View Analyst Price Targets for Scpharmaceuticals. What is the consensus analysts' recommendation for Scpharmaceuticals? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Scpharmaceuticals in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Scpharmaceuticals. Has Scpharmaceuticals been receiving favorable news coverage? Media stories about SCPH stock have trended negative recently, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Scpharmaceuticals earned a news sentiment score of -2.0 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 8.0 out of 10, indicating that recent press coverage is very likely to have an effect on the stock's share price in the near future. Who are some of Scpharmaceuticals' key competitors? Some companies that are related to Scpharmaceuticals include Concert Pharmaceuticals (CNCE), Xenon Pharmaceuticals (XENE), Protagonist Therapeutics (PTGX), PhaseBio Pharmaceuticals (PHAS), Aduro BioTech (ADRO), Evelo Biosciences (EVLO), Mersana Therapeutics (MRSN), Aratana Therapeutics (PETX), Urovant Sciences (UROV), Calithera Biosciences (CALA), Verrica Pharmaceuticals (VRCA), Marinus Pharmaceuticals (MRNS), Kamada (KMDA), Lannett (LCI) and Syros Pharmaceuticals (SYRS). What other stocks do shareholders of Scpharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Scpharmaceuticals investors own include Adamas Pharmaceuticals (ADMS), Progenics Pharmaceuticals (PGNX), Catalyst Pharmaceuticals (CPRX), Omeros (OMER), Selecta Biosciences (SELB), Clearside Biomedical (CLSD), Dynavax Technologies (DVAX), Exelixis (EXEL), Fate Therapeutics (FATE) and Amicus Therapeutics (FOLD). Who are Scpharmaceuticals' key executives? Scpharmaceuticals' management team includes the folowing people: Mr. John H. Tucker, Pres, CEO, CFO & Director (Age 56)Dr. Pieter Muntendam, Consultant (Age 61)Ms. Rachael Nokes, Principal Accounting OfficerKatherine Taudvin, Director of Corp. Devel. & Investor RelationsDr. John Mohr Pharm.D., Sr. VP of Clinical Devel. & Medical Affairs When did Scpharmaceuticals IPO? (SCPH) raised $96 million in an IPO on Friday, November 17th 2017. The company issued 6,400,000 shares at a price of $14.00-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO. Who are Scpharmaceuticals' major shareholders? Scpharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (1.86%), Jacobs Levy Equity Management Inc. (0.13%), Parametric Portfolio Associates LLC (0.10%), SG Americas Securities LLC (0.09%) and Morgan Stanley (0.06%). Company insiders that own Scpharmaceuticals stock include 5Am Partners Iv, Llc and Ra Capital Healthcare Fund Lp. View Institutional Ownership Trends for Scpharmaceuticals. Which institutional investors are selling Scpharmaceuticals stock? SCPH stock was sold by a variety of institutional investors in the last quarter, including Parametric Portfolio Associates LLC, BlackRock Inc. and Morgan Stanley. View Insider Buying and Selling for Scpharmaceuticals. Which institutional investors are buying Scpharmaceuticals stock? SCPH stock was acquired by a variety of institutional investors in the last quarter, including Jacobs Levy Equity Management Inc. and SG Americas Securities LLC. Company insiders that have bought Scpharmaceuticals stock in the last two years include 5Am Partners Iv, Llc and Ra Capital Healthcare Fund Lp. View Insider Buying and Selling for Scpharmaceuticals. How do I buy shares of Scpharmaceuticals? Shares of SCPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Scpharmaceuticals' stock price today? One share of SCPH stock can currently be purchased for approximately $3.57. How big of a company is Scpharmaceuticals? Scpharmaceuticals has a market capitalization of $66.33 million. The company earns $-29,440,000.00 in net income (profit) each year or ($1.59) on an earnings per share basis. Scpharmaceuticals employs 21 workers across the globe. What is Scpharmaceuticals' official website? The official website for Scpharmaceuticals is http://www.scpharma.com/. How can I contact Scpharmaceuticals? Scpharmaceuticals' mailing address is 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA, 01830. The company can be reached via phone at 617-517-0730 or via email at [email protected] MarketBeat Community Rating for Scpharmaceuticals (NASDAQ SCPH)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 104 (Vote Outperform)Underperform Votes: 96 (Vote Underperform)Total Votes: 200MarketBeat's community ratings are surveys of what our community members think about Scpharmaceuticals and other stocks. Vote "Outperform" if you believe SCPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SCPH will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/26/2019 by MarketBeat.com StaffFeatured Article: What factors cause inflation to rise? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.